Pharmacogenetics and Pharmacokinetics of Oxycodone to Personalize Postoperative Pain Management Following Thoracic Surgery in Adults

What this Trial Is About

Researchers are evaluating personalized postoperative pain management for adults undergoing major thoracic surgery such as pneumonectomy, lobectomy, and segmentectomy. The study focuses on two commonly used oral opioid painkillers, oxycodone and methadone, to better predict and manage pain and opioid-related side effects after surgery. The goal is to reduce severe post-surgical pain, chronic post-surgical pain (CPSP), opioid-related adverse events, and long hospital stays by developing risk prediction tools based on genetic and clinical factors. The research uses a pharmacogenetic approach called GPS-Analgesics, which combines genetic information and clinical risk factors to predict individual responses to opioids and surgical pain. This observational study gathers data on pain levels, opioid use, and adverse effects up to 12 months after surgery, aiming to improve personalized pain relief strategies. The study builds on previous findings that genetic differences significantly influence pain perception and opioid responses. Participants will undergo regular assessments of postoperative nausea and vomiting, sedation, respiratory depression, pain scores, opioid use, hospital stay length, and risks of opioid dependence and use disorder. The study collects information from before surgery through up to 12 months afterward to evaluate both short- and long-term outcomes. This comprehensive monitoring helps researchers understand the effectiveness of personalized pain management and its impact on recovery and opioid-related risks.

Personalized Postoperative Pain Management Following Thoracic Surgery in Adults